Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Holding GOSS?
Track your performance easily
GOSS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $1.60
Previous CloseN/A
Volume602.63K
Average Volume (3M)1.81M
Market Cap
$226.60M
Enterprise Value$99.86M
Total Cash (Recent Filing)$60.00K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Mar 21, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding226,604,140
10 Day Avg. Volume1,268,746
30 Day Avg. Volume1,811,640
Standard Deviation0.24
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.99
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue0.95
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.84
Forecast
1Y Price Target
$8.33Price Target Upside733.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Gossamer Bio News
PremiumCompany Announcements
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentSeralutinib led to further reductions in pulmonary vascular resistance, suggesting durable persistence of treatment effect.
Financial StabilityThe company reiterates their cash runway guidance into the first half of 2027, suggesting financial stability for the near future.
Strategic PartnershipsThe development and co-commercialization collaboration with Chiesi, an Italian pharmaceutical company, may accelerate development of seralutinib in PH-ILD.
Bears Say
Clinical TrialsTEAEs led to study discontinuation in 18 (24.3%) patients, most due to cough.
Financial PerformanceGOSS reported a net loss of $30.8M, indicating financial challenges despite having $327M in cash.
Safety ConcernsTwo patients discontinued seralutinib due to increased alanine transaminase to aspartate transaminase ratio (ALT/AST), key safety biomarkers in the liver, which resolved upon discontinuation.
---
Ownership Overview
9.40% Insiders
10.44% Mutual Funds
0.04% Other Institutional Investors
74.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.50 and its highest was $1.60 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $226.60M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Mar 21, 2025 which is in 62 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Nov 07, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.007.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.17.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 226,604,140 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
---
Gossamer Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (733.00% Upside)
$8.33 (733.00% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.18%
12-Months-Change
Fundamentals
Return on Equity
-90.26%
Trailing 12-Months
Asset Growth
0.85%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
---
GOSS Stock 12 Month Forecast
Average Price Target
$8.33
▲(733.00% Upside)
Technical Analysis
BioCryst
―
Immunovant
―
Blueprint Medicines
―
Rigel
―
Fate Therapeutics
―
Corbus Pharmaceuticals
―
Best Analysts Covering GOSS
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-16.44%
assigned a buy rating 4 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -16.44% per trade.
---